RANKL inhibition with Denosumab, a fully humanized antibody, improves bone-metastasis free survival in patients with breast cancer, prostate cancer and other solid tumors, an effect known to be associated with prevention of RANKL-RANK signaling on osteoclasts (139–141). Here, TNFSF11 is linked to prostate carcinoma.